Tag: pain

  • Epidural Steroid Injections: A Powerful Tool in Chronic Pain Management


    An Overview

    Epidural steroid injections (ESIs) are among the most effective non-surgical treatments for chronic spinal pain. For decades, they’ve been used to treat conditions like sciatica, herniated discs, and spinal stenosis—especially when pain radiates from the neck or lower back into the arms or legs. These injections not only reduce inflammation but can also prevent the progression of certain pain conditions.

    In this article, we’ll explore the history of epidural blocks, how they work, who benefits most, and what risks and benefits patients should understand before pursuing this treatment.


    A Brief History of Epidural Injections

    Epidural anesthesia dates back over a century, but the use of corticosteroids in the epidural space began in the 1950s as physicians sought ways to treat radicular pain non-surgically. Over the years, the technique evolved with improved imaging guidance and safety protocols, making it a mainstay of interventional pain management.

    Today, epidural injections are one of the most commonly performed procedures in pain clinics and are backed by decades of clinical use and research.


    How Epidural Steroid Injections Work

    The epidural space surrounds the spinal cord and nerve roots. Inflammation or compression of these nerves—often from disc herniation or spinal arthritis—can cause severe, radiating pain. By delivering a corticosteroid and a local anesthetic directly into this space, the injection reduces inflammation and helps calm irritated nerves.

    In many cases, patients experience significant relief within a few days. The steroid works to reduce the underlying inflammation, while the anesthetic provides temporary numbing of the affected nerve roots.


    Common Conditions Treated with Epidural Injections

    Epidural steroid injections are used for a range of spinal pain syndromes, including:

    • Lumbar and cervical radiculopathy (sciatica, pinched nerves)
    • Spinal stenosis
    • Herniated or bulging discs
    • Degenerative disc disease
    • Post-laminectomy syndrome (also called failed back surgery syndrome)
    • Thoracic radicular pain in select cases

    In some pain practices, epidural injections may also be used as part of a multimodal approach for complex regional pain syndrome (CRPS).


    Are Epidural Steroid Injections Disease-Modifying?

    While epidural injections don’t reverse structural spine changes, they can interrupt the cycle of inflammation and nerve sensitization. In certain patients—especially those with acute radicular pain—this can prevent progression to chronic pain.

    Some studies suggest early epidural intervention may reduce the need for surgical discectomy in patients with confirmed nerve root compression. In this way, the injections may have a disease-modifying effect by halting the development of chronic neuropathic pain.


    Who Should Perform Epidural Injections?

    These injections must be performed by properly trained physicians using image guidance (typically fluoroscopy or CT). Qualified specialists include:

    • Pain medicine physicians (usually anesthesiology or PM&R trained)
    • Interventional radiologists
    • Neurologists with procedural training

    Proper patient selection, sterile technique, and precise targeting are critical to both effectiveness and safety.


    Ideal Candidates for Epidural Blocks

    Epidural steroid injections are best suited for patients who:

    • Have pain that radiates into the limbs (radiculopathy)
    • Show imaging findings that correlate with symptoms (e.g., disc herniation)
    • Have not responded to physical therapy or medications
    • Are not ready for surgery or have contraindications to it
    • Need rapid pain relief to participate in rehab

    They are particularly useful in the subacute phase (6–12 weeks), where inflammation is still a significant driver of symptoms.


    Benefits of Epidural Injections

    Epidural injections are low-risk, outpatient procedures that offer:

    • Relief from nerve-related pain
    • Improved ability to participate in physical therapy
    • Reduced use of systemic medications, especially opioids
    • Delay or avoidance of surgery
    • Minimal recovery time

    In many patients, a single injection provides relief for weeks or even months. Some may benefit from a short series of two to three injections over a few months.


    Risks and Side Effects

    Though generally safe, epidural injections are not without risk. Potential complications include:

    • Dural puncture and headache
    • Bleeding (especially in patients on anticoagulants)
    • Infection (e.g., epidural abscess, meningitis)
    • Transient numbness or weakness
    • Steroid-related side effects (elevated blood sugar, flushing, insomnia)

    These risks are minimized when injections are performed with imaging by experienced clinicians.

    In 2014, the FDA issued a safety notice regarding serious neurologic events with unmonitored spinal injections. This underscores the importance of using image guidance and appropriate patient selection.


    The Role of Nerve Ablation as an Adjunct

    For patients whose pain is not primarily caused by nerve root inflammation but rather from facet joint arthritis, radiofrequency ablation (RFA) may be a better option. This procedure targets the medial branch nerves that transmit facet joint pain, using thermal energy to block pain signals.

    Often, a diagnostic nerve block is used to determine whether a patient is likely to benefit from RFA. In patients with both radicular and facet pain, epidural injections and ablation may be used together as part of a customized plan.


    Use in the Elderly and Non-Surgical Candidates

    Epidural injections are particularly valuable in older adults or patients who cannot undergo surgery due to:

    • Frailty
    • Cardiopulmonary conditions
    • Bleeding risk
    • Poor bone health (e.g., osteoporosis)

    For these individuals, ESIs provide a safer, conservative alternative to surgery and a pathway back to function with less reliance on systemic pain medications.


    Final Thoughts

    Epidural steroid injections remain a vital option in managing chronic spine-related pain. When used judiciously, they offer effective, targeted relief with a favorable safety profile. They can be especially beneficial in delaying surgery, enabling physical therapy, and reducing the burden of chronic pain in both younger and older patients.

    If you or your patients suffer from persistent nerve-related back or neck pain, consultation with a board-certified pain specialist may be the next best step.


    References

    1. Cohen SP et al. Epidural steroids: a comprehensive, evidence-based review. Reg Anesth Pain Med. 2013;38(3):175-200.
    2. Manchikanti L et al. Comprehensive evidence-based guidelines for interventional techniques in chronic spinal pain. Pain Physician. 2013;16(2 Suppl):S49-283.
    3. FDA. Epidural corticosteroid injection: Drug Safety Communication. 2014.
    4. Dreyfuss P et al. Radiofrequency neurotomy for lumbar facet pain. Spine. 2000;25(10):1270–1277.

  • A New Era in Pain Management: Understanding Suzetrigine

    A New Era in Pain Management: Understanding Suzetrigine

    The FDA’s approval of suzetrigine (Journavx) on January 30, 2025, marks a watershed moment in pain medicine – the first new class of pain medication in over two decades[1]. This breakthrough couldn’t come at a more critical time, as our nation grapples with an opioid epidemic that has claimed countless lives while leaving millions suffering from undertreated pain.

    The Opioid Crisis and the Need for Innovation

    The story of pain management in America is complex. Over a 15-year period from 1999 to 2014, opioid prescriptions nearly doubled from 105 million to 207 million, with fatal overdoses increasing five-fold[5]. This crisis created a challenging paradox: how do we effectively treat pain while avoiding the risks of addiction? More than 50 million American adults live with chronic pain, half experiencing severe pain daily[51]. The stigma surrounding opioid use has created additional barriers, with many patients facing discrimination in healthcare settings and reluctance from providers to prescribe needed medications[6].

    The Science Behind Suzetrigine

    Suzetrigine represents a completely novel approach to pain management. Unlike opioids, which work in the brain to dull pain perception, suzetrigine targets a specific protein called NaV1.8, found only in pain-sensing nerve cells in the peripheral nervous system[7]. This sodium channel plays a crucial role in transmitting pain signals from injured tissue to the brain. By selectively blocking NaV1.8, suzetrigine prevents pain signals from being generated in the first place[3].

    The drug’s development was inspired by an fascinating discovery – researchers studied a family of fire walkers in Pakistan who could walk on hot coals without pain due to a genetic variation affecting their pain-sensing nerves[3]. It took scientists 25 years to translate this finding into a therapeutic approach.

    Clinical Evidence and Effectiveness

    In large clinical trials involving over 2,000 patients, suzetrigine demonstrated significant pain relief following surgeries like abdominoplasty and bunionectomy[1]. The drug works relatively quickly – patients experienced meaningful pain reduction within 119-240 minutes, compared to 480 minutes with placebo[55]. On a standard 0-10 pain scale, suzetrigine typically reduced pain scores by about 3.5 points[3].

    Safety Profile and Practical Considerations

    The medication is taken orally, with a loading dose of 100mg followed by 50mg every 12 hours[3]. Common side effects are generally mild, including headache, constipation, itching, muscle spasms, and occasional rash[54]. Importantly, suzetrigine shows no evidence of addiction potential or dependence[7].

    One key limitation: the drug shouldn’t be taken with strong CYP3A inhibitors or grapefruit products[2]. A week’s course of treatment costs approximately $232.50, though insurance coverage is expected to expand given its inclusion under the NOPAIN Act[1].

    Future Potential

    While currently approved only for acute pain, ongoing research is exploring suzetrigine’s potential in chronic pain conditions[57]. Early studies in sciatica have shown mixed results, but researchers remain optimistic about its potential broader applications[57]. The drug’s unique mechanism of action suggests it could be effective for both musculoskeletal and neuropathic pain conditions.

    Changing the Pain Management Paradigm

    Suzetrigine represents more than just a new medication – it signals a shift toward more targeted, safer approaches to pain management. For healthcare providers long caught between the imperative to treat pain and the risks of opioid prescribing, it offers a valuable new tool. For patients, it provides hope for effective pain relief without the stigma and risks associated with opioids.

    The approval of suzetrigine reminds us that scientific innovation can help address even our most challenging healthcare crises. As we continue to battle the opioid epidemic while working to better serve patients in pain, this new class of medication may help chart a path forward.

    Sources
    [1] Suzetrigine’s Pending Approval Signals a Shift in Non-Opioid Pain … https://www.medcentral.com/pain/suzetrigine-pending-approval-signals-a-shift-in-non-opioid-pain-management
    [2] [PDF] JOURNAVX (suzetrigine) tablets, for oral use – accessdata.fda.gov https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219209s000lbl.pdf
    [3] FDA approves first new type of pain medication in 25 years – CNN https://www.cnn.com/2025/01/30/health/fda-approves-painkiller-suzetrigine-journavx/index.html
    [4] Nonopioid Therapies for Pain Management | Overdose Prevention https://www.cdc.gov/overdose-prevention/hcp/clinical-care/nonopioid-therapies-for-pain-management.html
    [5] Opioid epidemic: How are we teaching future doctors to treat pain? https://health.ucdavis.edu/news/headlines/opioid-epidemic-how-are-we-teaching-future-doctors-to-treat-pain/2024/04
    [6] The Impact of Stigma on People with Opioid Use Disorder, Opioid … https://pmc.ncbi.nlm.nih.gov/articles/PMC8800858/
    [7] Pharmacology and Mechanism of Action of Suzetrigine, a Potent … https://pubmed.ncbi.nlm.nih.gov/39775738/
    [8] Can this new drug promise pain relief without peril? https://news.northwestern.edu/stories/2025/01/can-this-new-drug-promise-pain-relief-without-peril/
    [9] Pain meets precision medicine – C&EN – American Chemical Society https://cen.acs.org/pharmaceuticals/drug-development/Pain-meets-precision-medicine/103/i3
    [10] Pain Management Alternatives to Opioids https://www.mhs.net/patients-and-visitors/pain-management
    [11] [PDF] JOURNAVX (suzetrigine) tablets, for oral use – Vertex Pharmaceuticals https://pi.vrtx.com/files/uspi_suzetrigine.pdf
    [12] Suzetrigine – Wikipedia https://en.wikipedia.org/wiki/Suzetrigine
    [13] Non-Opioid Treatment for Chronic Pain | Made for This Moment https://madeforthismoment.asahq.org/pain-management/non-opioid-treatment/
    [14] Vertex to Present Phase 3 Data Highlighting Suzetrigine’s Potential … https://news.vrtx.com/news-releases/news-release-details/vertex-present-phase-3-data-highlighting-suzetrigines-potential
    [15] Nonopioid Pharmacologic Treatments for Chronic Pain https://effectivehealthcare.ahrq.gov/products/nonopioid-chronic-pain/protocol
    [16] Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a … https://news.vrtx.com/news-releases/news-release-details/vertex-announces-fda-approval-journavxtm-suzetrigine-first-class
    [17] US drug agency approves potent painkiller — the first non-opioid in … https://www.nature.com/articles/d41586-025-00274-1
    [18] FDA Approves Novel Non-Opioid Treatment for Moderate to Severe … https://www.fda.gov/news-events/press-announcements/fda-approves-novel-non-opioid-treatment-moderate-severe-acute-pain
    [19] FDA Approves Suzetrigine, New Alternative to Opioids for Acute Pain https://www.pharmacytimes.com/view/fda-approves-suzetrigine-new-alternative-to-opioids-for-acute-pain
    [20] Suzetrigine: Uses, Interactions, Mechanism of Action – DrugBank https://go.drugbank.com/drugs/DB18927
    [21] Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a … https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-fda-approval-journavxtm-suzetrigine-first-class
    [22] FDA Greenlights Review of Vertex’s Suzetrigine for Severe Acute Pain https://havenhealthmgmt.org/fda-greenlights-review-of-vertexs-suzetrigine-for-severe-acute-pain/
    [23] The best non-opioid relief for serious pain – Aetna https://www.aetna.com/health-guide/non-opioid-painkillers.html
    [24] Journavx (suzetrigine) FDA Approval History – Drugs.com https://www.drugs.com/history/journavx.html
    [25] Alternatives to Opioids for Managing Pain – StatPearls – NCBI https://www.ncbi.nlm.nih.gov/books/NBK574543/
    [26] [PDF] alternatives to opioids – Florida Department of Health https://www.floridahealth.gov/programs-and-services/non-opioid-pain-management/_documents/alternatives-facts-11×17-eng.pdf
    [27] What Is Journavx, the New Opioid-Free Painkiller from Vertex? https://www.scientificamerican.com/article/what-is-journavx-the-new-opioid-free-painkiller-from-vertex/
    [28] New Non-Opioid Compound Provides Innovative Pain Relief https://dental.nyu.edu/aboutus/news/articles/397.html
    [29] Non opioid drugs | Cancer Research UK https://www.cancerresearchuk.org/about-cancer/coping/physically/cancer-and-pain-control/treating-pain/painkillers/types-of-painkillers/non-opioids
    [30] Guiding Principles for Addressing the Stigma on Opioid Addiction https://americanhealth.jhu.edu/news/guiding-principles-addressing-stigma-opioid-addiction
    [31] Pain Management and the Opioid Epidemic – NCBI Bookshelf https://www.ncbi.nlm.nih.gov/books/NBK458655/
    [32] End the Stigma campaign – State of Michigan https://www.michigan.gov/opioids/find-help/stigma/stigma-info/campaign
    [33] Opioid Use Disorder – Psychiatry.org https://www.psychiatry.org/patients-families/opioid-use-disorder
    [34] Stigma around drug use – Canada.ca https://www.canada.ca/en/health-canada/services/opioids/stigma.html
    [35] Addressing the Opioid Crisis | ACL Administration for Community … https://acl.gov/programs/addressing-opioid-crisis
    [36] Stigma Reduction | Stop Overdose – CDC https://www.cdc.gov/stop-overdose/stigma-reduction/index.html
    [37] Perceived stigma, barriers, and facilitators experienced by members … https://sigmapubs.onlinelibrary.wiley.com/doi/full/10.1111/jnu.12837
    [38] Breaking barriers: addressing opioid stigma in chronic pain https://journals.lww.com/pain/fulltext/9900/breaking_barriers__addressing_opioid_stigma_in.770.aspx
    [39] Vertex Announces Results From Phase 2 Study of Suzetrigine for … https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-results-phase-2-study-suzetrigine-treatment
    [40] Can this new drug promise pain relief without peril? https://news.northwestern.edu/stories/2025/01/can-this-new-drug-promise-pain-relief-without-peril/
    [41] FDA approves first new type of pain medication in 25 years – CNN https://www.cnn.com/2025/01/30/health/fda-approves-painkiller-suzetrigine-journavx/index.html
    [42] Suzetrigine: First-in-Class Nonopioid Pain Therapy Is Approved by … https://www.ajmc.com/view/suzetrigine-the-first-non-opiate-pain-therapy-is-fda-approved
    [43] [PDF] Suzetrigine for Acute Pain:Effectiveness and Value – ICER https://icer.org/wp-content/uploads/2025/02/ICER_Acute-Pain_Evidence-Report_For-Publication_020525.pdf
    [44] Suzetrigine (Journavx), an Opioid Alternative for Pain – GoodRx https://www.goodrx.com/conditions/pain/opioid-alternatives
    [45] FDA Approves New Non-Opioid Pain Treatment – WebMD https://www.webmd.com/pain-management/news/20250131/fda-approves-new-non-opioid-pain-treatment
    [46] Journavx: Uses, Dosage, Side Effects, Warnings – Drugs.com https://www.drugs.com/journavx.html
    [47] What to Know About Journavx, the Non-Opioid Pain Medication Just … https://www.usnews.com/news/health-news/articles/2025-01-31/what-to-know-about-journavx-the-non-opioid-pain-medication-just-approved-by-the-fda
    [48] Journavx (suzetrigine) dosing, indications, interactions … – Medscape https://reference.medscape.com/drug/journavx-suzetrigine-4000474
    [49] Chronic Pain Management and Opioid Misuse: A Public Health … https://www.aafp.org/about/policies/all/chronic-pain-management-opiod-misuse.html
    [50] Public stigma of opioid addiction – Recovery Research Institute https://www.recoveryanswers.org/research-post/public-stigma-opioid-addiction-opioid-use-disorder-medical-illness/
    [51] The Opioid Crisis – NIH HEAL Initiative https://heal.nih.gov/about/opioid-crisis
    [52] Stigma as a fundamental hindrance to the United States opioid … https://pmc.ncbi.nlm.nih.gov/articles/PMC6957118/
    [53] The Opioid Epidemic and Cancer Pain Management – NCI https://www.cancer.gov/news-events/cancer-currents-blog/2018/opioid-crisis-cancer-pain-paice
    [54] FDA Approves Vertex Pharmaceuticals’ Suzetrigine for Acute Pain … https://www.neurologylive.com/view/fda-approves-vertex-pharmaceuticals-suzetrigine-acute-pain-management
    [55] Suzetrigine’s Pending Approval Signals a Shift in Non-Opioid Pain … https://www.medcentral.com/pain/suzetrigine-pending-approval-signals-a-shift-in-non-opioid-pain-management
    [56] Institute for Clinical and Economic Review Publishes Evidence … https://icer.org/news-insights/press-releases/institute-for-clinical-and-economic-review-publishes-evidence-report-on-treatment-for-acute-pain/
    [57] FDA Approves the First Non-Opioid Pain Drug in 20 Years – Time https://time.com/7211657/fda-approves-non-opioid-pain-drug-suzetrigine/
    [58] [PDF] SUZETRIGINE (VX-548) ASA UPDATE https://investors.vrtx.com/static-files/39514f75-f903-4a34-a729-7b1646b4b0f9